MSRA polymorphism is associated with the risk of rheumatoid arthritis in a Chinese population. (March 2013)

• Record Type: Journal Article
• Authors: Zhang, Y; Zhang, H; Zhuang, C; Liu, R; Wei, J
• Is Part Of: Scandinavian journal of rheumatology. Volume 42:Number 2(2013)
• Page Start: 91
• Page End: 96
• Publication Date: 2013-03
• Subjects: Rheumatology -- Periodicals; Arthritis; Rheumatic Diseases; 616.72005
• DOI: 10.3109/03009742.2012.730626
• Languages: English
• ISSNs: 0300-9742

Abstract

Abstract : Objectives: The expression of receptor activator of methionine sulfoxide reductase A (MSRA) and that of receptor activator of nuclear factor-kappa B (NF-κB) ligand (RANKL) are closely related to rheumatoid arthritis (RA). Our aim was to confirm whether MSRA and RANKL polymorphisms play a role in RA in a Chinese population. Methods: We investigated the presence of MSRA rs10903323 G/A and RANKL rs7984870 C/G polymorphisms in 329 patients with RA and 697 controls in a Chinese population. Genotyping was performed using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Results: When the MSRA rs10903323 GG homozygote genotype was used as the reference group, the GA genotype was associated with a significantly increased risk for RA. In the dominant model, when the MSRA rs10903323 GG homozygote genotype was used as the reference group, the GA/AA genotypes were associated with a significantly increased susceptibility to RA. The RANKL rs7984870 C/G polymorphism was not associated with a risk for RA. In stratification analyses, a significantly increased risk for RA associated with the MSRA rs10903323 GA genotype was evident among male patients, older patients, C-reactive protein (CRP)-positive patients, and anti-cyclic citrullinated peptide (anti-CCP) negative patients compared with the MSRA rs10903323 GG genotype. Conclusions: These findings suggest that the MSRA rs10903323 G/A variant allele is associated with RA development, especially among male patients, older patients, CRP-positive patients, and anti-CCP negative patients.